This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
North Chicago, IL-based AbbVie has become one of the top-most pharma companies after it acquired Botox maker Allergan in a cash-and-stock deal for $63 billion in May 2020. The deal is expected to transform AbbVie’s portfolio and lower its dependence on Humira, its flagship product, which has already lost patent protection in Europe and is due to face biosimilar competition in the United States in 2023. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest drugs Skyrizi (risankizumab) and Rinvoq (upadacitinib) position it well for long-term growth.
Merck's ADC Drug Gets FDA Breakthrough Therapy Tag in NSCLC
by Zacks Equity Research
This is the first breakthrough therapy designation granted to MRK's sacituzumab tirumotecan in the United States.
Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock
by Zacks Equity Research
AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
J&J Seeks FDA Approval for Tremfya for Psoriasis in Kids
by Zacks Equity Research
J&J files for FDA approval of Tremfya for plaque psoriasis and psoriatic arthritis indications in pediatric patients
Is First Trust Capital Strength ETF (FTCS) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FTCS
Why Is AbbVie (ABBV) Down 10.2% Since Last Earnings Report?
by Zacks Equity Research
AbbVie (ABBV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
TEVA Stock Down 10% in a Month: Should You Buy the Dip?
by Kinjel Shah
Teva's reasonable valuation, an improving pipeline, and sales and profit growth potential are good enough reasons for those who own the stock to stay invested.
Should You Invest in the Vanguard Health Care ETF (VHT)?
by Zacks Equity Research
Sector ETF report for VHT
AbbVie Stock Rises After Leerink Partners Upgrades Its Rating
by Zacks Equity Research
Leerink Partners upgrades its rating on ABBV stock from Market Perform to Outperform.
J&J Seeks FDA Nod for Subcutaneous Tremfya as Induction Regimen in UC
by Zacks Equity Research
If approved, JNJ's Tremfya will be the first IL-23 inhibitor to offer a choice of subcutaneous or intravenous use as induction treatment in ulcerative colitis.
Is Trending Stock AbbVie Inc. (ABBV) a Buy Now?
by Zacks Equity Research
AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
ALDX Up as FDA Accepts Resubmitted NDA for Eye Drug Reproxalap
by Zacks Equity Research
The FDA accepts Aldeyra's resubmitted NDA for topical ocular reproxalap to treat the signs and symptoms of dry eye disease. Stock rises.
AbbVie's Ovarian Cancer Drug Elahere Gets Approval in Europe
by Zacks Equity Research
The European Commission approves ABBV's Elahere for the treatment of platinum-resistant ovarian cancer.
Pharma Stock Roundup: AZN, BAYRY's Earnings, ABBV's Pipeline Setback
by Kinjel Shah
AZN and BAYRY announce Q3 results. ABBV's studies on schizophrenia candidate, emraclidine, fail to meet goal.
AbbVie Stock Falls 11% in a Month: Should You Buy the Dip?
by Kinjel Shah
Investors who own ABBV stock may stay invested as the company has faced its biggest challenge quite well and looks set to return to robust growth next year.
Should First Trust Morningstar Dividend Leaders ETF (FDL) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for FDL
Syros Stock Plunges as Lead Cancer Study Fails to Meet Primary Goal
by Zacks Equity Research
SYRS stock plummets as late-stage cancer study of lead candidate fails to achieve its primary endpoint leading to the termination of the study.
AbbVie Stock Declines as Schizophrenia Studies Fail, BMY Gains
by Zacks Equity Research
ABBV stock tumbles 13% after two mid-stage schizophrenia studies on emraclidine fail to meet their primary endpoint. BMY stock rises.
Company News for Nov 12, 2024
by Zacks Equity Research
Companies In The News Are: ICL, ARMK, ABBV, SPNS.
Ironwood's Q3 Earnings Lag Estimates, Revenues Top, Stock Down
by Zacks Equity Research
IRWD's third-quarter earnings miss estimates while revenues beat the same. The company maintains revenue guidance for 2024. Stock falls.
Is Arcellx (ACLX) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Arcellx, Inc. (ACLX) and AbbVie (ABBV) have performed compared to their sector so far this year.
Wall Street Bulls Look Optimistic About AbbVie (ABBV): Should You Buy?
by Zacks Equity Research
The average brokerage recommendation (ABR) for AbbVie (ABBV) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
Zacks Investment Ideas feature highlights: AbbVie, Visa and Comfort Systems USA
by Zacks Equity Research
AbbVie, Visa and Comfort Systems USA are part of the Zacks Investment Ideas article.
Dividend Watch: Three Companies Boosting Quarterly Payouts
by Derek Lewis
Earnings season continues to move at a rapid pace, with many companies reporting daily. And recently, these three companies delivered news of higher dividend payouts.
RHHBY or ABBV: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
RHHBY vs. ABBV: Which Stock Is the Better Value Option?
TEVA Stock Down 7% Despite Q3 Earnings & Sales Beat, Guidance Increase
by Zacks Equity Research
TEVA reports better-than-expected third-quarter results, beating both earnings and sales estimates. However, the stock declines 7%.